142 related articles for article (PubMed ID: 36149549)
1. Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer.
Yokota H; Sato K; Sakamoto S; Okuda Y; Fukuda N; Asano M; Takeda M; Nakayama K; Miura M
Invest New Drugs; 2022 Dec; 40(6):1254-1262. PubMed ID: 36149549
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
[TBL] [Abstract][Full Text] [Related]
3. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Kobayashi H; Sato K; Niioka T; Miura H; Ito H; Miura M
Clin Lung Cancer; 2015 Jul; 16(4):274-81. PubMed ID: 25554506
[TBL] [Abstract][Full Text] [Related]
4. Association of
Tanda M; Yamamoto K; Hori T; Nishiguchi H; Yagi M; Shimizu M; Konishi T; Ozaki T; Yoshioka N; Tachihara M; Ito T; Ikushima S; Omura T; Yano I
Anticancer Res; 2023 Apr; 43(4):1775-1783. PubMed ID: 36974789
[TBL] [Abstract][Full Text] [Related]
5. Effects of polymorphisms in pregnane X receptor and ABC transporters on afatinib in Japanese patients with non-small cell lung cancer: pharmacogenomic-pharmacokinetic and exposure-response analysis.
Yokota H; Sato K; Sakamoto S; Okuda Y; Asano M; Takeda M; Nakayama K; Miura M
Cancer Chemother Pharmacol; 2023 Oct; 92(4):315-324. PubMed ID: 37500985
[TBL] [Abstract][Full Text] [Related]
6. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
[TBL] [Abstract][Full Text] [Related]
7. Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.
Abumiya M; Mita A; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N; Miura M
Med Oncol; 2018 May; 35(6):90. PubMed ID: 29736778
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
9. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.
Kato H; Sassa N; Miyazaki M; Takeuchi M; Asai M; Iwai A; Noda Y; Gotoh M; Yamada K
Cancer Chemother Pharmacol; 2016 Oct; 78(4):855-62. PubMed ID: 27586968
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.
Ishikawa E; Yokoyama Y; Chishima H; Kasai H; Kuniyoshi O; Kimura M; Hakamata J; Nakada H; Suehiro N; Nakaya N; Nakajima H; Ikemura S; Kawada I; Yasuda H; Terai H; Jibiki A; Kawazoe H; Soejima K; Muramatsu H; Suzuki S; Nakamura T
Invest New Drugs; 2023 Feb; 41(1):122-133. PubMed ID: 36637703
[TBL] [Abstract][Full Text] [Related]
11. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
12. Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects.
Li J; Wang X; Ning C; Wang Z; Wang Y; Zheng M; Zhang S; Lu Y; Zhang Y; Li N; Chen X; Zhao D
Eur J Clin Pharmacol; 2020 Aug; 76(8):1125-1133. PubMed ID: 32382947
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
[TBL] [Abstract][Full Text] [Related]
14. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
15. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Veerman GDM; Boosman RJ; Jebbink M; Oomen-de Hoop E; van der Wekken AJ; Bahce I; Hendriks LEL; Croes S; Steendam CMJ; de Jonge E; Koolen SLW; Steeghs N; van Schaik RHN; Smit EF; Dingemans AC; Huitema ADR; Mathijssen RHJ
EClinicalMedicine; 2023 May; 59():101955. PubMed ID: 37125403
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
17. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
18. Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Kobayashi H; Sato K; Niioka T; Takeda M; Okuda Y; Asano M; Ito H; Miura M
Med Oncol; 2016 Jun; 33(6):57. PubMed ID: 27154635
[TBL] [Abstract][Full Text] [Related]
19. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
20. Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of
Song H; Bai W; Sun X; Qiu B; Guo N; Guo C; Hu Y; Dong Z
Xenobiotica; 2021 Dec; 51(12):1463-1469. PubMed ID: 34979850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
